The test relies on a signature that Almac developed for stratifying breast cancer patients, but which, as the researchers showed, can be used in other cancers as well.
The JHU technology leverages an epigenetic biomarker panel and a sponge-on-a-string collection device, as well as a PCR-based method, to detect Barrett's esophagus.
With sequence data for 551 esophageal adenocarcinomas, researchers uncovered potential prognostic alterations and mutations that may sensitize tumors to treatment.
DNA sequence data from hundreds of individuals suggest that age, smoking, and alcohol use coincide with the expansion of clones containing NOTCH1 and PPM1D mutations.
In PNAS this week: immune cell profiling of wild baboons by social status, metabolomics profiling of esophageal tumors, and more.
The company beat the consensus Wall Street estimate on the top line and guided to 2018 revenues of between $21 million and $22 million.
In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.
Researchers saw frequent somatic mutations in esophageal tissue from nine individuals, including mutations under positive selection in 14 oncogenes.
Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.
Priorities for Q3 include the continued buildup of a commercial launch for the company's BarreGEN test. The firm has started a second clinical validation study for the test.
Three genetic testing companies form a coalition to influence how Congress considers genetic privacy, The Hill reports.
University of California, San Diego researchers investigate how skin care products influence the skin microbiome, Scientific American reports.
The Wall Street Journal examines billing codes used by uBiome.
In PNAS this week: links between lung adenocarcinoma and lncRNA, algorithm to impute and cluster Hi-C interaction profiles from single cells, and more.